Leading biopharmaceutical company selects clinivation’s Prospectus™ commercial strategy suite of business intelligence and analytics software to achieve knowledge dominance of the anti-infectives therapeutic business space.
Framingham, MA, October 5, 2001 – clinivation, Inc. announced today that Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) has selected clinivation’s Prospectus™ commercial strategy suite of business intelligence and analytics software.
“Cubist is the industry’s emerging leader in anti-infectives biopharmaceuticals, and we are pleased that they have selected our strategic intelligence and analytics software,” said Joseph Kozikowski, M.D., Chairman and Chief Technology Officer of clinivation.
The solution, which will include a customized portal interface to be deployed at Cubist under the name “CUBASE,” will deliver comprehensive clinical and commercial business intelligence with highly-usable query and reporting features. The solution will improve and accelerate the processes of strategic diligence, pipeline commercialization, and portfolio architecture, and will include users in corporate development, marketing, sales, patents, development, and other job functions.
“Our goal is for Cubist to know more than anyone else about their business space. We will achieve this goal by integrating data from numerous proprietary and legacy sources, building a scalable knowledge repository, and distributing that knowledge with highly-usable reporting and query interfaces,” Dr. Kozikowski continued.
About Cubist Pharmaceuticals, Inc.
Cubist Pharmaceuticals, Inc. is focused on becoming a global leader in the research, development and commercialization of novel antimicrobial drugs to combat serious and life-threatening bacterial and fungal infections. Cubist is evaluating the safety and efficacy of Cidecin(R) (daptomycin for injection) in the EDGE(TM) (Evaluation of Daptomycin against Gram-positive Entities) clinical trial program and has broadened its pipeline to include multiple pre- clinical drug candidates. The Company is engaged in strategic partnerships with Novartis Pharma AG and Merck & Co for the discovery and development of novel antiinfectives and with Gilead Sciences for the commercialization of daptomycin in Europe. Cubist is headquartered in Lexington, MA and has operations in Vancouver, BC, Canada and Slough, UK.
For more information about Cubist Pharmaceuticals, Inc., visit the Company’s Web site at www.cubist.com
